NewGenIvf Group (NASDAQ:NIVF) Director Kong Yiu Cheung Purchases 500,000 Shares of Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung acquired 500,000 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were bought at an average cost of $1.33 per share, with a total value of $665,000.00. Following the completion of the acquisition, the director owned 1,222,223 shares in the company, valued at $1,625,556.59. This represents a 69.23% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung bought 2,500,000 shares of NewGenIvf Group stock. The stock was purchased at an average price of $1.00 per share, with a total value of $2,500,000.00.

NewGenIvf Group Stock Down 1.4%

NIVF opened at $1.33 on Wednesday. The business has a 50 day moving average price of $2.96 and a two-hundred day moving average price of $11.34. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.98 and a current ratio of 3.12. NewGenIvf Group Limited has a 1-year low of $1.15 and a 1-year high of $1,539.00.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on NIVF shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. Wall Street Zen raised shares of NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.